SCHEMBL2568299

SCHEMBL2568299

O=S(=O)(Nc1ccccc1F)c1ccccc1

nearest known ligand 0.73

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RECQL P46063 1/20 0.58
ALDH1A1 P00352 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
TSHR P16473 2/20 0.56
PSIP1 O75475 1/20 0.56
RXFP1 Q9HBX9 1/20 0.56
SLC22A12 Q96S37 1/20 0.56
IL1RN P18510 1/20 0.55
KEAP1 Q14145 1/20 0.55
ERAP1 Q9NZ08 1/20 0.55
LIMK2 P53671 1/20 0.55
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
HTR2C P28335 1/20 0.54
HTR2B P41595 1/20 0.54
GRM4 Q14833 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7854392 0.89 TSHR (0.70) TSHRRXFP1KEAP1MEN1KMT2A
SCHEMBL6760868 0.87 RECQL (0.57) RECQLALDH1A1SMN1; SMN2TSHRIL1RN
SCHEMBL7090449 0.85 CA1 (0.64) TSHRRXFP1KEAP1MEN1KMT2A
SCHEMBL3072539 0.85 LMNA (0.70) ALDH1A1SMN1; SMN2TSHRKEAP1
SCHEMBL2067538 0.85 ALDH1A1 (0.68) RECQLALDH1A1SMN1; SMN2IL1RNKEAP1
SCHEMBL6394653 0.82 GRM4 (0.57) TSHRKEAP1MEN1KMT2AGRM4
SCHEMBL5801171 0.82 LMNA (0.61) TSHRKEAP1MEN1KMT2A
SCHEMBL5480533 0.81 POLB (0.62) ALDH1A1SMN1; SMN2TSHRMEN1KMT2A
SCHEMBL21893366 0.81 CA2 (0.62) ALDH1A1SMN1; SMN2TSHRRXFP1MEN1
SCHEMBL398719 0.81 KDM4E (0.71) ALDH1A1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2382191-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS Abbott Laboratories, Inc. (US) 2011-11-02 EP claimed
CN-104136435-A BROMODOMAIN INHIBITORS ABBVIE INC 2014-11-05 CN disclosed
EP-2382191-A1 NOVEL BENZENESULFONAMIDES AS CALCIUM CHANNEL BLOCKERS Abbott Laboratories, Inc. (US) 2011-11-02 EP disclosed
US-20030162817-A1 Pentafluorobenzenesulfonamides and analogs TULARIK INC. 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162817-A1 Pentafluorobenzenesulfonamides and analogs FGFR1, FPR1, FGF1 RECQL 4221/4885ALDH1A1 1192/4885SMN1; SMN2 4509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.